Dr. Youssoufian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
18 Fairfield Street
Boston, MA 02116Phone+1 617-631-5112
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteResidency, Hematology and Medical Oncology, 1987 - 1989
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1986
Cleveland Clinic FoundationResidency, Internal Medicine, 1983 - 1985
University of Massachusetts Medical SchoolClass of 1983
Certifications & Licensure
TX State Medical License Active through 2014
American Board of Medical Genetics and Genomics Clinical Genetics
Clinical Trials
- An Open-label Extension Study of PSMA ADC 2301 in mCRPC Start of enrollment: 2013 Oct 01
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Start of enrollment: 2016 Oct 01
- A Study of ADXS-NEO Expressing Personalized Tumor Antigens Start of enrollment: 2018 Mar 28
- Join now to see all
Publications & Presentations
PubMed
- CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid t...J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung
BJC Reports. 2025-02-27 - 1 citationsGOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients w...Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro
International Journal of Gynecological Cancer. 2025-01-06 - 7 citationsThe phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi
Nature Communications. 2024-03-11
Abstracts/Posters
- Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...Hagop Youssoufian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with MyelofibrosisHagop Youssoufian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Gadeta Appoints Scientific Advisory Board and Provides Business UpdateOctober 20th, 2022- Bob Goeltz Bolts Unity Biotechnology to Become CFO at Arcus Biosciences; John Johnson Tapped for His Latest CEO GigJuly 10th, 2020
Chutes & Ladders—Biogen Executive Kress Takes over the Reins of SyntimmuneJanuary 5th, 2018- Join now to see all
Grant Support
- Medical Genetics Research Fellowship ProgramNational Institute Of General Medical Sciences2000
- Phenotype Screens For Bone Marrow FailureNational Heart, Lung, And Blood Institute2000
- Molecular Analysis Of Fanconi'S Anemia C ProteinNational Heart, Lung, And Blood Institute2000
- Molecular Analysis Of Fanconis Anemia C ProteinNational Heart, Lung, And Blood Institute1997–1999
- Molecular Analysis Of Fanconis Anemia C ProteinNational Heart, Lung, And Blood Institute1995–1996
- Biogenesis Of The Red Cell Membrane And CytoskeletonNational Heart, Lung, And Blood Institute1991–1993
- Biogenesis Of The Red Cell Membrane And CytoskeletonNational Heart, Lung, And Blood Institute1989–1991
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
